The state-wide surveillance program for human ehrlichia infections was conducted between 1995 and 2000 in order to characterize the prevalence and annual incidence of ehrlichiosis and its spectrum of disease symptoms.
The initial landmark trials of Rotateq and Rotarix—rotavirus vaccines approved for widespread use in 2006 and 2008, respectively—revealed impressive efficacy and safety profiles from a large cohort of various countries, as well as a reduction in rates of hospitalizations, and emergency room and office visits. However, none of these studies were conducted in the United States. Accordingly, this study’s primary aim is to assess the effectiveness of the recently licensed rotavirus vaccines in preventing hospitalization, and emergency room and office visits, in young children specifically in a US clinical setting. This study will provide a generalizable model and better understanding of the vaccines’ effectiveness in the current setting of the US health care system.